Hematologic Cancers

Tiffany Richards expresses her positive outlook on daratumumab, citing that the treatment has helped extend life expentancies.
Tiffany Richards provides an overview of the most common questions she hears from patients regarding daratumumab.
Tiffany Richards discusses the numerous, often unmet, needs of patients with multiple myeloma.
Tiffany Richards shares anecdotes that illustrate why it's important to really know your patients in order to effectively care for them.
Tiffany Richards stresses the importance of educating patients about side effects and what to do when these side effects begin to present.
Tiffany Richards is excited about all the new multiple myeloma treatments that are being introduced, but understands that the question of how to best utilize these drugs still remains to be answered.
Tiffany Richards insists on the importance of survivorship care in patients with multiple myeloma and explains how to make sure patients stay as healthy as possible for as long as possible.
Daratumumab therapy is successful in patients with multiple myeloma who have received ≥3 previous lines of therapy, including a proteasome inhibitor and an immunomodulatory drug (IMiD), or whose disease is double-refractory to those other drugs.
In 2015, the combination of bortez­omib, lenalidomide, and dexamethasone was shown to improve survival outcomes versus lenalidomide and dexamethasone alone in patients with newly diagnosed multiple myeloma. However, this triplet therapy also increased patients’ risk for severe peripheral neuropathy.
Daratumumab is a human CD38 IgGκ monoclonal antibody that demonstrated significant activity and a manageable safety profile when used in combination with bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.
Page 3 of 9
Results 21 - 30 of 86